Cognitive Behavioural Therapy/Metacognitive Therapy for Low Self Esteem

NCT ID: NCT06866639

Last Updated: 2025-03-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-01
• Study Completion Date: 2026-08-01

Brief Summary

The goal for this clinical trial is to explore the effect of CBT/MCT on the treatment of low self esteem. 20 patients with low self-esteem will be selected and distributed into two either MCT or a CBT

We aim in this study to (1) evaluate the accessibility and effectiveness of MCT and CBT in treating low self-esteem, (2) investigate the patterns of change and the mechanisms of action involved during treatment, and (3) examine the impact of meta-cognitions and neuropsychologial processes in the treatment response and any relapse prevention of low self-esteem.

Detailed Description

The association between low self-esteem and psychiatric disorders indicates that low self-esteem is an important transdiagnostic construct. People who report having a low self-esteem seem to experience more mental health problems and a reduction in quality of life.

There have been a few trials considering the effect of Cognitive Behavioural Therapy (CBT) for low self-esteem, however, there are few randomized controlled studies. Recently, Meta Cognitive Therapy (MCT) has been introduced as a new, specific treatment for MDD, showing promising and lasting results. This treatment approach also has proven more effective than CBT for GAD or worry disorder. So far, no study has examined MCT for low self-esteem in a randomized controlled trial.

For the present clinical trial, 20 patients with low self-esteem will be selected and distributed into two treatment conditions. The first group (n=10) will be treated with MCT, whereas the second group (n = 10) will be treated with CBT. The patients will be assessed with different outcome measures at pre-treatment, at the end of treatment, and at six months follow up. In addition, they will also be assessed weekly using various measures.

We aim in this study to (1) evaluate the accessibility and effectiveness of MCT and CBT in treating low self-esteem, (2) investigate the patterns of change and the mechanisms of action involved during treatment, and (3) examine the impact of meta-cognitions and neuropsychologial processes in the treatment response and any relapse prevention of low self-esteem.

Conditions

Psychological Disorders

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cognitive behavioral therapy

Cognitive behavioral therapy

Group Type: EXPERIMENTAL

Cognitive behavioral therapy

Intervention Type: BEHAVIORAL

The CBT is based on the treatment manual written by Fennell (1997). The patients receiving CBT will be treated for 8 sessions, with weekly session of 45-60 minutes duration.

Metacognitive therapy

Metacognitive therapy

Group Type: EXPERIMENTAL

Metacognitive therapy

Intervention Type: BEHAVIORAL

The meta-cognitive treatment program is based on Wells's metacognitive therapy (Wells, 2013). The patients receiving meta-cognitive therapy will be treated for 8 sessions, with weekly session of 45-60 minutes duration.

Interventions

Cognitive behavioral therapy

The CBT is based on the treatment manual written by Fennell (1997). The patients receiving CBT will be treated for 8 sessions, with weekly session of 45-60 minutes duration.

Intervention Type: BEHAVIORAL

Metacognitive therapy

The meta-cognitive treatment program is based on Wells's metacognitive therapy (Wells, 2013). The patients receiving meta-cognitive therapy will be treated for 8 sessions, with weekly session of 45-60 minutes duration.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

1. Signed written informed consent obtained prior to entry in the study.

2. Scores below 15 on the Rosenberg Self-esteem Scale (RSE)

3. 18 years or older.

Exclusion Criteria

1. Psychosis

2. Bipolar type 1

3. Current suicide intent

4. PTSD

5. Cluster A or cluster B personality disorder

6. Substance dependence

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Norwegian University of Science and Technology

OTHER

Sponsor Role: collaborator

University of Oslo

OTHER

Sponsor Role: lead

Responsible Party

Roger Hagen

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Roger Hagen, Professor

Role: PRINCIPAL_INVESTIGATOR

University of Oslo

Locations

Department of Psychology, University of Oslo

Oslo, , Norway

Countries

Norway

Central Contacts

Roger Hagen, Professor

Role: CONTACT

roger.hagen@psykologi.uio.no

+4748109789

Leif Edward Ottesen Kennair, Professor

Role: CONTACT

Kennair@ntnu.no

+4790557004

Facility Contacts

Roger Hagen

Role: primary

roger.hagen@ntnu.no

48109789

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

LSE06064685

Identifier Type: -

Identifier Source: org_study_id